IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
Relative valuation derived from Healthcare sector median benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Multiples adjusted for extreme outliers and non-recurring volatility.
Auditing capital efficiency...
Quality Profile Audit
Score: 50GRADE C+
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation.
Return on Equity
Profit generated per dollar of shareholder equity
29.1%
Sector: -43.5%
Dividend Analysis audit
No Dividend
This company does not currently pay a dividend.
Analyst Projections
Analyst Consensus
Unlock Valuation Tools
Sign up for free access to institutional-quality research tools.
Based on our 6-factor quantitative model, PUMA BIOTECHNOLOGY, INC. (PBYI) receives a "Hold" rating with a composite score of 52.1/100, ranked #698 out of 4446 stocks. Key factor scores: Quality 50/100, Value 74/100, Momentum 70/100. This is quantitative analysis only — not investment advice.
PUMA BIOTECHNOLOGY, INC. (PBYI) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does PUMA BIOTECHNOLOGY, INC. Do?
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. PUMA BIOTECHNOLOGY, INC. (PBYI) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Alan H. Auerbach and employs approximately 200 people, headquartered in LOS ANGELES, California. With a market capitalization of $344M, PBYI is one of the notable companies in the Healthcare sector.
PUMA BIOTECHNOLOGY, INC. (PBYI) Stock Rating — Hold (April 2026)
As of April 2026, PUMA BIOTECHNOLOGY, INC. receives a Hold rating with a composite score of 52.1/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.PBYI ranks #698 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, PUMA BIOTECHNOLOGY, INC. ranks #43 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
PBYI Stock Price and 52-Week Range
PUMA BIOTECHNOLOGY, INC. (PBYI) currently trades at $7.71. The stock lost $0.08 (1.1%) in the most recent trading session. The 52-week high for PBYI is $7.68, which means the stock is currently trading 0.5% from its annual peak. The 52-week low is $2.58, putting the stock 199.6% above its annual trough. Recent trading volume was 200K shares, suggesting relatively thin trading activity.
Is PBYI Overvalued or Undervalued? — Valuation Analysis
PUMA BIOTECHNOLOGY, INC. (PBYI) carries a value factor score of 74/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 9.33x, compared to the Healthcare sector average of 23.63x — a discount of 61%. The price-to-book ratio stands at 2.72x, versus the sector average of 2.75x. The price-to-sales ratio is 1.52x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, PBYI trades at 7.06x EV/EBITDA, versus 6.34x for the sector. The EV/EBIT multiple is 8.08x.
Based on these multiples, PUMA BIOTECHNOLOGY, INC. appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.
PUMA BIOTECHNOLOGY, INC. Profitability — ROE, Margins, and Quality Score
PUMA BIOTECHNOLOGY, INC. (PBYI) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 29.1%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 17.6% versus the sector average of -33.1%.
On a margin basis, PUMA BIOTECHNOLOGY, INC. reports gross margins of 73.8%, compared to 71.5% for the sector. The operating margin is 16.6% (sector: -66.1%). Net profit margin stands at 14.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 15.7% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
PBYI Debt, Balance Sheet, and Financial Health
PUMA BIOTECHNOLOGY, INC. has a debt-to-equity ratio of 17.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.00x, suggesting adequate working capital coverage. Total debt on the balance sheet is $23M. Cash and equivalents stand at $54M.
PBYI has a beta of 1.22, meaning it is more volatile than the broader market — a $10,000 investment in PBYI would be expected to move 22.4% more than the S&P 500 on any given day. The stability factor score for PUMA BIOTECHNOLOGY, INC. is 55/100, reflecting average volatility within the normal range for its sector.
PUMA BIOTECHNOLOGY, INC. Revenue and Earnings History — Quarterly Trend
In TTM 2026, PUMA BIOTECHNOLOGY, INC. reported revenue of $233M and earnings per share (EPS) of $0.62. Net income for the quarter was $38M. Gross margin was 73.8%. Operating income came in at $42M.
In FY 2025, PUMA BIOTECHNOLOGY, INC. reported revenue of $228M and earnings per share (EPS) of $0.62. Net income for the quarter was $31M. Gross margin was 74.5%. Revenue grew -0.9% year-over-year compared to FY 2024. Operating income came in at $37M.
In Q3 2025, PUMA BIOTECHNOLOGY, INC. reported revenue of $54M and earnings per share (EPS) of $0.18. Net income for the quarter was $9M. Gross margin was 77.6%. Revenue grew -32.4% year-over-year compared to Q3 2024. Operating income came in at $10M.
In Q2 2025, PUMA BIOTECHNOLOGY, INC. reported revenue of $52M and earnings per share (EPS) of $0.12. Net income for the quarter was $6M. Gross margin was 76.5%. Revenue grew 11.4% year-over-year compared to Q2 2024. Operating income came in at $7M.
Over the past 8 quarters, PUMA BIOTECHNOLOGY, INC. has demonstrated a growth trajectory, with revenue expanding from $47M to $233M. Investors analyzing PBYI stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
PBYI Dividend Yield and Income Analysis
PUMA BIOTECHNOLOGY, INC. (PBYI) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
PBYI Momentum and Technical Analysis Profile
PUMA BIOTECHNOLOGY, INC. (PBYI) has a momentum factor score of 70/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 27/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 4/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
PBYI vs Competitors — Healthcare Sector Ranking and Peer Comparison
Comparing PBYI against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PBYI vs S&P 500 (SPY) comparison to assess how PUMA BIOTECHNOLOGY, INC. stacks up against the broader market across all factor dimensions.
PBYI Next Earnings Date
No upcoming earnings date has been announced for PUMA BIOTECHNOLOGY, INC. (PBYI) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy PBYI? — Investment Thesis Summary
PUMA BIOTECHNOLOGY, INC. presents a balanced picture with arguments on both sides. The value score of 74/100 suggests attractive pricing relative to fundamentals. Price momentum is positive at 70/100, suggesting the trend favors buyers.
In summary, PUMA BIOTECHNOLOGY, INC. (PBYI) earns a Hold rating with a composite score of 52.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PBYI stock.
We'll email you when stocks you follow change their composite rating.
Institutional Research Dossier
PUMA BIOTECHNOLOGY, INC. (PBYI) Deep Dive Analysis
Published on March 24, 2026
Action RatingHold
Sections
Executive Summary
Puma Biotechnology is currently rated a Hold, and this assessment appears justified based on a balanced view of its financial performance and future prospects. While the company exhibits strong profitability metrics and trades at attractive valuation multiples compared to its sector, its reliance on a single product and the inherent risks associated with the pharmaceutical industry warrant caution. The critical takeaway is that while Puma presents a compelling value proposition, investors should closely monitor its pipeline development and competitive landscape before considering a more aggressive position.
The company's impressive profitability, as evidenced by its high ROE and margins, coupled with its low valuation multiples, suggests potential undervaluation. However, the concentration risk associated with Nerlynx, its primary revenue driver, and the potential for generic competition or clinical trial setbacks temper enthusiasm. A Hold rating reflects the need for further evidence of diversification and sustained growth before upgrading to a Buy recommendation.
Business Strategy & Overview
Puma Biotechnology operates as a biopharmaceutical company focused on developing and commercializing therapies to improve cancer care. Its primary revenue source is Nerlynx (neratinib), an oral drug approved for extended adjuvant treatment of HER2-positive early-stage breast cancer following adjuvant trastuzumab-based therapy. The company's strategy revolves around maximizing the commercial potential of Nerlynx through various indications and geographic expansions, while also exploring new drug candidates for HER2-positive cancers and other solid tumors.
The company generates revenue primarily through direct sales of Nerlynx in the United States and through licensing agreements with partners for commercialization in other regions. These agreements typically involve upfront payments, milestone payments, and royalties on sales. Puma's strategic positioning hinges on addressing unmet needs in the HER2-positive breast cancer space, particularly in patients who have completed initial treatment but remain at risk of recurrence. The company aims to differentiate Nerlynx through its efficacy in reducing recurrence rates and its convenient oral administration.
Puma's product pipeline includes ongoing clinical trials evaluating Nerlynx in combination with other therapies for advanced or metastatic HER2-positive breast cancer and HER2 mutation-positive solid tumors. These trials are crucial for expanding the drug's label and addressing a broader patient population. The company also invests in research and development to identify and develop new drug candidates, although Nerlynx remains its primary focus. The success of Puma's strategy depends on its ability to effectively commercialize Nerlynx, secure regulatory approvals for new indications, and advance its pipeline of novel therapies.
The pharmaceutical industry is characterized by intense competition, high regulatory hurdles, and significant research and development costs. Puma faces competition from established pharmaceutical companies with larger resources and broader product portfolios. The company must navigate a complex regulatory landscape to obtain and maintain marketing approvals for its products. Furthermore, the risk of clinical trial failures and the emergence of generic competition pose significant challenges to Puma's long-term growth prospects.
Execution Benchmarks audit
Revenue Growth
YOY expansion rate
15.7%
Sector: 10.6%
+48% VS SCTR
Economic Moat Analysis
Puma Biotechnology's economic moat is best characterized as Narrow. While the company benefits from certain advantages, they are not substantial enough to create a wide and sustainable competitive edge. The primary source of Puma's moat is its intellectual property protection for Nerlynx, which provides a period of market exclusivity. This exclusivity allows Puma to generate revenue without direct generic competition, at least for a limited time.
However, the patent protection for Nerlynx is not indefinite, and the threat of generic entry looms in the future. Once the patents expire, generic manufacturers can enter the market, eroding Puma's market share and pricing power. Furthermore, the pharmaceutical industry is characterized by intense competition, with numerous companies developing and marketing therapies for breast cancer. This competition limits Puma's ability to raise prices or capture a dominant market share.
Puma does not possess significant network effects or switching costs. While physicians may become familiar with Nerlynx and its efficacy, there are alternative treatments available, and patients can switch to other therapies if they are more effective or have fewer side effects. The company also does not have a significant cost advantage over its competitors. The manufacturing and distribution of pharmaceuticals are subject to strict regulations and require specialized expertise, but Puma does not have a unique cost structure that gives it a significant edge.
The intangible assets associated with Nerlynx, such as its brand reputation and clinical data, provide some competitive advantage. However, these assets are not insurmountable, and competitors can develop and market competing therapies with similar efficacy and safety profiles. Therefore, while Puma benefits from patent protection and some intangible assets, its economic moat is relatively narrow and vulnerable to competition and generic entry.
Financial Health & Profitability
Puma Biotechnology's financial health presents a mixed picture. The company exhibits strong profitability metrics, with a TTM ROE of 29.2% significantly exceeding the sector average of -42.5%. Its gross margin of 73.8% is also slightly above the sector average of 71.9%, while its operating and net margins of 16.6% and 14.8%, respectively, are substantially higher than the sector averages of -65.2% and -54.1%. This indicates efficient cost management and a profitable core business.
Revenue growth has been volatile. While the TTM revenue growth of 15.7% is higher than the sector average of 10.7%, a closer look at the quarterly financial history reveals fluctuations. FY2024 saw a slight increase in revenue compared to FY2023, but Q2 and Q1 of FY2024 showed net losses, contrasting with the profitability observed in the subsequent quarters and FY2025. This inconsistency raises concerns about the sustainability of revenue growth and profitability.
The company's balance sheet appears relatively healthy. With total cash of $53.52 million and total debt of $22.68 million, Puma has a manageable debt-to-equity ratio of 17.00, lower than the sector average of 30.00. The current ratio of 2.00 indicates sufficient liquidity to meet short-term obligations. Free cash flow generation is also positive, with a TTM FCF of $35.30 million, suggesting the company is capable of funding its operations and investments.
However, the lack of FCF data for recent quarters limits a comprehensive assessment of cash flow trends. The significant increase in net income and EPS in FY2025 compared to FY2023 and FY2024 is a positive sign, but it is essential to monitor whether this trend continues. Overall, Puma's financial health is characterized by strong profitability and a healthy balance sheet, but revenue growth volatility and limited cash flow data warrant caution.
Valuation Assessment
Puma Biotechnology's valuation appears attractive based on several key metrics. The company's P/E ratio of 9.9x is significantly lower than the healthcare sector average of 24.3x, suggesting potential undervaluation. Similarly, its EV/EBITDA ratio of 1.7x is substantially below the sector average of 6.4x, further indicating that the company may be undervalued relative to its earnings potential.
However, it's crucial to consider the company's growth prospects and risk profile when assessing its valuation. While Puma has demonstrated revenue growth in the past, the sustainability of this growth is uncertain, given its reliance on a single product and the competitive landscape of the pharmaceutical industry. The company's valuation may reflect investor concerns about these risks.
A discounted cash flow (DCF) analysis would provide a more comprehensive valuation assessment, but without detailed projections of future cash flows, it is difficult to determine a precise fair value for the stock. However, based on the available data, Puma's current valuation appears reasonable, if not slightly undervalued, given its profitability and growth potential. The market may be discounting the stock due to concerns about the company's reliance on Nerlynx and the potential for generic competition.
Compared to its historical valuation, Puma's current multiples are relatively low. The company's P/E ratio has fluctuated significantly in the past, reflecting changes in its earnings and investor sentiment. However, the current P/E ratio is near the lower end of its historical range, suggesting that the stock may be undervalued relative to its historical performance. Overall, Puma's valuation appears attractive based on its current multiples, but investors should carefully consider its growth prospects and risk profile before making an investment decision.
Risk & Uncertainty
Puma Biotechnology faces several specific, idiosyncratic risks that could negatively impact its business and financial performance. The most significant risk is its heavy reliance on Nerlynx, which currently accounts for the vast majority of its revenue. Any adverse event affecting Nerlynx, such as clinical trial failures, regulatory setbacks, or the emergence of competing therapies, could have a material impact on the company's financial results.
Another significant risk is the potential for generic competition. Once the patents protecting Nerlynx expire, generic manufacturers can enter the market, eroding Puma's market share and pricing power. The timing and extent of generic competition are uncertain, but it is a significant threat to the company's long-term revenue stream. Furthermore, Puma faces regulatory risks associated with obtaining and maintaining marketing approvals for its products. Changes in regulatory requirements or adverse findings during regulatory inspections could delay or prevent the approval of new indications for Nerlynx or other drug candidates.
Puma also faces competition from established pharmaceutical companies with larger resources and broader product portfolios. These companies may develop and market competing therapies that are more effective or have fewer side effects than Nerlynx. The company's ability to compete effectively depends on its ability to differentiate Nerlynx and secure a significant market share. Finally, Puma's financial performance is subject to fluctuations in foreign exchange rates, as it generates revenue from international sales. Changes in exchange rates could negatively impact the company's reported revenue and earnings.
Bulls Say / Bears Say
The Bull Case
BULL VIEWPuma's low P/E and EV/EBITDA ratios compared to the sector suggest it's significantly undervalued, offering substantial upside potential as the market recognizes its profitability.
BULL VIEWNerlynx's continued market penetration and potential label expansions will drive sustained revenue growth, making Puma an attractive investment in the oncology space.
The Bear Case
BEAR VIEWPuma's over-reliance on a single drug, Nerlynx, makes it highly vulnerable to competition and patent expiration, threatening its long-term revenue stream.
BEAR VIEWThe inconsistent quarterly financial performance and lack of consistent FCF data raise concerns about the sustainability of Puma's profitability and growth.
About the Author
Marques Blank
Founder & Chief Investment Officer, Blank Capital
Marques brings 15 years of institutional finance and investing experience, having overseen financial planning for a $1.6B defense business unit. He developed the proprietary 6-factor quantitative model used to score PBYI and 4,400+ other equities.
PUMA BIOTECHNOLOGY, INC. exhibits a 15% valuation discount relative to institutional benchmarks. This represents a constructive entry window based on current multiples.
Return on Assets
Efficiency of asset utilization
17.6%
Sector: -33.1%
Gross Margin
Pricing power and cost efficiency
73.8%
Sector: 71.5%
Operating Margin
Core business profitability
16.6%
Sector: -66.1%
Net Margin
Bottom-line profitability
14.8%
Sector: -58.7%
Factor Methodology
The Quality factor evaluates the persistence and magnitude of cash flows. Companies with scores >70 exhibit superior competitive moats and financial resilience through economic cycles.
